Show simple item record

dc.contributor.authorRedick, Thomas P
dc.date.accessioned2017-06-08T17:34:44Z
dc.date.available2017-06-08T17:34:44Z
dc.date.issued2013
dc.identifier.urihttps://hdl.handle.net/1813/51413
dc.description.abstractBiotech specialty crops face a number of potential barriers. Regulatory uncertainty over new plant-breeding methods and costly overseas approvals could complicate plans for commercialization. Stacking a generic crop aids innovators in the marketplace, but generic crops may need the regulatory data held by patent holders to achieve regulatory approval. Sustainability standards may arbitrarily deny use of biotechnology. Any innovator heading into this sector will need to be aware of all the potential threats awaiting these exciting opportunities in genetic engineering of biotech crops.
dc.language.isoen_US
dc.publisherNABC
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAgricultural biotechnology
dc.subjectspecialty crops
dc.subjecttransgenic papaya
dc.subjectstakeholders
dc.subjectgenetic engineering
dc.subjectGE
dc.subjectGMO
dc.subjectregulation
dc.subjectfood safety
dc.subjectUSDA
dc.subjectnovel traits
dc.subjectpremarket approval
dc.subjectintellectual property
dc.subjectpatents
dc.subjecthuman health impacts
dc.subjectsynthetic genomics
dc.titleThe “stacked” pipeline of biotech specialty crops and regulatory/market barriers to coexistence
dc.typebook chapter


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

Statistics